Breakthrough infection could provide broad protection against current SARS-CoV-2 variants of concern

A delta breakthrough infection generates a potent and broad neutralizing antibody response in double vaccinated individuals, according to new research. The findings were published this week in mBio, an open-access journal of the American Society for Microbiology.

In the new study, researchers collected sera from individuals attending St. Thomas' Hospital in London who tested positive for COVID-19 and had received 2 doses of either the Pfizer or AstraZeneca vaccines. They measured how much antibody the person produced and whether the antibodies were able to prevent infection of cells by different SARS-CoV-2 variants of concern. 

The researchers found that in vaccinated individuals, there was a rapid and robust IgG recall response following breakthrough infection. This antibody response had broad neutralizing activity against current variants of concern, including omicron. The neutralization potency was 4.5-fold reduced against omicron compared to delta whereas it was 28.9-fold reduced for people who were unvaccinated.

Overall, a breakthrough infection effectively boosts the vaccine response, which could provide broad protection against current variants of concern. Recent studies show a third vaccine dose dramatically increases the neutralizing antibody response, particularly against omicron. Our data suggests a delta breakthrough infection can also act as an effective booster. This study provides insights into population immunity in double COVID-19 vaccinated individuals where SARS-CoV-2 transmission levels remain high."

Katie Doores, Ph.D., Co-Author, Reader in the Department of Infectious Diseases, King's College London, in the United Kingdom

Dr. Doores said they are now studying the immune response in more detail by isolating monoclonal antibodies from individuals experiencing breakthrough infections.

Source:
Journal reference:

Lechmere, T., et al. (2022) Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. mBio. doi.org/10.1128/mbio.03798-21.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trial shows felzartamab reduces proteinuria in IgA nephropathy patients